Management of anaphylaxis: A systematic review

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 2, 2014, Pages 168-175

  Dhami, S ^a   Panesar, S S ^b   Roberts, G ^c,d,e   Muraro, A ^f   Worm, M ^g   Bilo M B ^h   Cardona, V ⁱ   Dubois, A E J ^j   Dunngalvin, A ^k   Eigenmann, P ^l   Fernandez Rivas, M ^m   Halken, S ⁿ   Lack, G ^o,p   Niggemann, B ^g   Rueff, F ^q   Santos, A F ^o,p,r   Vlieg Boerstra, B ^s   Zolkipli, Z Q ^c,d   Sheikh, A ^b,t  

^a Evidence Based Health Care Ltd   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h OSPEDALI RIUNITI   (Italy)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k UNIVERSITY COLLEGE CORK   (Ireland)

^l Children's Hospital   (Switzerland)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁿ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^o KING'S COLLEGE LONDON   (United Kingdom)

^p KING'S COLLEGE LONDON   (United Kingdom)

^q UNIVERSITY OF MUNICH   (Germany)

^r CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^s EMMA CHILDREN S HOSPITAL   (Netherlands)

^t BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

adrenaline; anaphylaxis; antihistamines; emergency management plans; immunotherapy

Indexed keywords

ADRENALIN; ALLERGEN; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLXANTHINE; SNAKE VENOM ANTISERUM; VENOM;

ANAPHYLAXIS; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; FATALITY; HEALTH EDUCATION; HUMAN; IMMUNOTHERAPY; INTERVENTION STUDY; LONG TERM CARE; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT COURSE THERAPY; SNAKEBITE; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; THERAPY DELAY; VASTUS LATERALIS MUSCLE;

ADRENALINE; ANAPHYLAXIS; ANTIHISTAMINES; EMERGENCY MANAGEMENT PLANS; IMMUNOTHERAPY;

ANAPHYLAXIS; BRONCHODILATOR AGENTS; EPINEPHRINE; HUMANS;

EID: 84893045853     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12318     Document Type: Review

References (62)

1. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier B, Lockey R, et al. A revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of World Allergy Organization. J Allergy Clin Immunol 2004; 113: 832-836. (Pubitemid 38608590)
2. Muraro A, Roberts G, Clark A, Eigenmann PA, Halken S, Lack G, et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy 2007; 62: 857-871. (Pubitemid 47037857)
3. American Academy of Pediatrics, Committee on School Health. Guidelines for urgent care in school. Pediatrics 1990; 86: 999-1000.
4. International Collaborative Study of Severe Anaphylaxis. An epidemiologic study of severe anaphylactic and anaphylactoid reactions among hospital patients: methods and overall risks. Epidemiology 1998; 9: 141-146.
5. Australasian Society of Clinical Immunology and Allergy Inc. (ASCIA). Guidelines for EpiPen prescription. ASCIA Anaphylaxis Working Party 2004. Available online at http://www.allergy.org.au/anaphylaxis/epipen-guidelines.htm Last accessed on 20th September 2012
6. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; and Joint Council of Allergy, Asthma, and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 15 (Suppl 3): S483-S523.
7. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock A, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117: 391-397. (Pubitemid 43190153)
8. Walker S, Sheikh A,. Managing anaphylaxis: effective emergency and long-term care are necessary. Clin Exp Allergy 2003; 33: 1015-1018. (Pubitemid 36976224)
9. Dhami S, Panesar SS, Rader T, Muraro A, Roberts G, Worm M, et al. The acute and long-term management of anaphylaxis: protocol for a systematic review. Clin Transl Allergy 2013; 3: 14.
10. International Prospective Register of Systematic Reviews (PROSPERO http://www.crd.york.ac.uk/prospero): CRD42013003703.
11. Agresti A, Coull BA,. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998; 52: 119-126.
12. Sheikh A, Shehata YA, Brown SG, Simons FE,. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2008; CD006312.
13. Sheikh A, Shehata YA, Brown SG, Simons FE,. Adrenaline for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2012; CD006312.
14. Sheikh A, Simons FER, Barbour V, Worth A,. Adrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the community. Cochrane Database Syst Rev 2012; 8, dOI: 10.1002/14651858.CD008935. pub2
15. Safdar B, Cone D, Pham K,. Subcutaneous epinephrine in the prehospital setting. Prehosp Emerg Care 2000; 5: 200-207. (Pubitemid 32322122)
16. Simons FE, Roberts J, Gu X, Simons K,. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101: 33-37. (Pubitemid 28112878)
17. Simons FE, Gu X, Simons K,. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108: 871-873. (Pubitemid 33096224)
18. Simons FE, Gu X, Johnston L, Simons K,. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics 2000; 106: 1040-1044.
19. Simons FER, Gu X, Silver N, Simons K,. EpiPen Jr versus EpiPen in young children weighing 15 to 30 kg at risk for anaphylaxis. J Allergy Clin Immunol 2002; 109: 171-175. (Pubitemid 34112148)
20. Jarvinen K, Sicherer S, Sampson H, Nowak-Wegrzyn A,. Use of multiple doses of epinephrine in food-induced anaphylaxis in children. J Allergy Clin Immunol 2008; 122: 133-138.
21. Soreide E, Buxrud T, Harboe S,. Severe anaphylactic reactions outside hospital: etiology, symptoms and treatment. Acta Anaesthesiol Scand 1988; 32: 339-342.
22. Bock S, Munoz-Furlong A, Sampson H,. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107: 191-193. (Pubitemid 32105265)
23. Bock S, Munoz-Furlong A, Sampson H,. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119: 1016-1018. (Pubitemid 46527814)
24. Pumphrey RSH,. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30: 1144-1150. (Pubitemid 30619768)
25. Pumphrey RH, Gowland H,. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119: 1018-1019.
26. Sampson HA, Mendelson L, Rosen JP,. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327: 380-384.
27. Choo K, Simons FE, Sheikh A,. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010; 65: 205-1211.
28. Choo K, Simons FE, Sheikh A,. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Rev 2012; CD007596.
29. Sheikh A, Ten Broek V, Brown GA, Simons FE,. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62: 830-837. (Pubitemid 47037864)
30. Sheikh A, Ten BV, Brown GA, Simons FE,. H1-antihistamines for the treatment of anaphylaxis with and without shock. Cochrane Database Syst Rev 2012; CD006160.
31. Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antihistamines. Ann Emerg Med 2000; 36: 462-468.
32. Runge J, Martinez JC, Caravati E, Williamson S, Hartsell S,. Histamine antihistamines in the treatment of acute allergic reactions. Ann Emerg Med 1992; 21: 237-242.
33. Ernst ME, Graber MA,. Methylxanthine use in anaphylaxis: what does the evidence tell us? Ann Pharmacother 1999; 33: 1001-1004. (Pubitemid 29421000)
34. Choo K, Sheikh A,. Action plans for the long-term management of anaphylaxis: systematic review of effectiveness. Clin Exp Allergy 2007; 37: 1090-1094. (Pubitemid 46955514)
35. Nurmatov U, Worth A, Sheikh A,. Anaphylaxis management plans for the acute and long-term management of anaphylaxis: a systematic review. J Allergy Clin Immunol 2008; 122: 353-361.
36. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 10: CD008838.
37. Ross R, Nelson H, Finegold I,. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 2000; 22: 351-358. (Pubitemid 30213141)
38. Watanabe A,. Specific-immunotherapy using Hymenoptera venom: systematic review. Sao Paulo Med J 2010; 128: 30-37.
39. Hockenhull J, Elremeli M, Cherry MG, Mahon J, Lai M, Darroch J, et al. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen for the treatment of bee and wasp venom allergy. Health Technol Assess 2012; 16: 1-110.
40. Brown S, Wiese M, Blackman K, Heddle R,. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003; 361: 1001-1006. (Pubitemid 36351369)
41. Golden D, Valentine M, Kagey-Sobotka A, Lichtenstein L,. Regimens of hymenoptera venom immunotherapy. Ann Intern Med 1980; 92: 620-624. (Pubitemid 10107551)
42. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM,. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299: 157-161. (Pubitemid 8396220)
43. Mosbech H, Malling H, Biering I, Bowadi H, Soborg M, Weeke B, et al. Immunotherapy with Yellow Jacket Venom. A comparative study including three different extracts, one adsorbed to Aluminium Hydroxide and two unmodified. Allergy 1986; 41: 95-103. (Pubitemid 16044349)
44. Müller U, Lanner A, Schmid P, Bischof M, Dreborg S, Hoigné R,. A double blind study on immunotherapy with chemically modified honey bee venom: monomethoxy polyethylene glycol-coupled versus crude honey bee venom. Int Arch Allergy Appl Immunol 1985; 77: 201-203.
45. Müller U, Rabson AR, Bischof M, Lomnitzer R, Dreborg S, Lanner A,. A double-blind study comparing glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. J Allergy Clin Immunol 1987; 80: 252-261. (Pubitemid 17132827)
46. Oude Elberink J, de Monchy J, van der Heide S, Guyatt H, Dubois A,. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110: 174-182. (Pubitemid 36132745)
47. Oude Elberink J, van der Heide S, Guyatt H, Dubois A,. Analysis of the burden of treatment in patients receiving an Epipen for yellow jacket anaphylaxis. J Allergy Clin Immunol 2006; 118: 174-182.
48. Quercia O, Rafanelli S, Puccinelli P, Stefanini F,. The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. J Investig Allergol Clin Immunol 2001; 11: 27-33. (Pubitemid 32586096)
49. Golden D, Kagey-Sobotka A, Valentine M, Lichtenstein L,. Prolonged maintenance interval in Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981; 67: 482-484. (Pubitemid 11117080)
50. Muller U, Thurnheer R, Patrizzi R, Spiess J, Hoigne R,. Immunotherapy in bee sting hypersensitivity. Allergy 1979; 34: 369-378.
51. Thurnheer U, Muller U, Stoller R, Lanner A, Hoigne R,. Venom Immunotherapy in hymenoptera sting allergy. Allergy 1983; 38: 465-475.
52. Spina J, Mcintyre L, Pulcini J,. An intervention to increase high school students compliance with carrying auto-injectable epinephrine: a MASNRN Study. J Sch Nurs 2012; 28: 230-237.
53. Manassis K,. Managing anxiety related to anaphylaxis in childhood: a systematic review. J Allergy (Cairo) 2012; 2012: 316296.
54. Habib A,. Effect of premedication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analyses. Drug Saf 2011; 34: 869-880.
55. De Silva H, Pathmeswaran A, Ranasinha C, Jayamanne S, Samarakoon B, Hittharage A, et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomized, double-blind, placebo=controlled trial. PLoS Med 2011; 8: e1000435.
56. Tramer M, von Elm E, Loubeyre P, Hauser C,. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 2006; 333: 675.
57. Walker S, Sheikh A,. Managing anaphylaxis: effective emergency and long-term care are necessary. Clin Exp Allergy 2003; 33: 1015-1018. (Pubitemid 36976224)
58. Ewan PW, Clark AT,. Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan. Lancet 2001; 357: 111-115. (Pubitemid 32094914)
59. Ewan PW, Clark AT,. Efficacy of a management plan based on severity assessment in longitudinal and case-controlled studies of 747 children with nut allergy: proposal for good practice. Clin Exp Allergy 2005; 35: 751-756. (Pubitemid 40961348)
60. Kapoor S, Roberts G, Bynoe Y, Gaughan M, Habibi P, Lack G,. Influence of a multidisciplinary paediatric allergy clinic on parental knowledge and rate of subsequent allergic reactions. Allergy 2004; 59: 185-191. (Pubitemid 38250774)
61. Kastner M, Harada L, Waserman S,. Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature. Allergy 2010; 65: 436-444.
62. Papadopoulos NG, Agache I, Bavbek S, Bilo BM, Braido F, Cardona V, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy 2012; 2: 21.